Welcome to our dedicated page for Atossa Therapeutics news (Ticker: ATOS), a resource for investors and traders seeking the latest updates and insights on Atossa Therapeutics stock.
Atossa Therapeutics, Inc. (Nasdaq: ATOS) is a clinical-stage biopharmaceutical company whose news flow centers on the development of its lead investigational therapy, (Z)-Endoxifen. Company announcements frequently cover progress in breast cancer programs, regulatory interactions, intellectual property developments, and emerging opportunities in other serious diseases.
Investors following ATOS news can expect regular updates on clinical trials involving (Z)-Endoxifen, including studies in metastatic ER+/HER2- breast cancer, neoadjuvant treatment for premenopausal ER+/HER2- patients, breast cancer risk reduction strategies focused on mammographic breast density, and participation in the RECAST DCIS platform trial for hormone receptor–positive ductal carcinoma in situ. These releases often summarize trial design, early findings, and the potential implications for future registration strategies.
Atossa’s news also highlights regulatory milestones, such as FDA Type C meetings, Investigational New Drug (IND) submissions, and “Study May Proceed” letters. Additional coverage includes the FDA’s Rare Pediatric Disease designation for (Z)-Endoxifen in Duchenne Muscular Dystrophy, as well as AI-enabled research collaborations identifying new oncology indications like glioblastoma.
Another recurring theme in ATOS news is the company’s intellectual property position, including newly issued patents for enteric oral (Z)-Endoxifen formulations and methods of use in hormone-dependent breast disorders and estrogen-related conditions. Corporate updates, such as financial results, leadership appointments, and Nasdaq listing communications, provide context on Atossa’s operational and strategic direction.
By monitoring this news page, readers can review a chronological record of Atossa’s clinical, regulatory, scientific, and corporate announcements related to (Z)-Endoxifen and the company’s broader oncology and rare disease programs.
Atossa Therapeutics (Nasdaq: ATOS) has received regulatory approval from the HREC to initiate a clinical study of its nebulized formulation AT-H201 in Australia. This therapy aims to assist both moderately to severely ill COVID-19 patients and long-haul patients suffering from post-infection pulmonary issues. The Phase 1/2a study will evaluate 60 participants and aims to determine the efficacy of AT-H201, which has shown promising potency in in vitro tests against SARS-CoV-2. Successful trial results and regulatory approvals are essential for commercialization.
Atossa Therapeutics (Nasdaq: ATOS) announced its inclusion in the Russell 2000 and Russell 3000 Indexes, effective June 28, 2021. This event follows the announcement of preliminary additions on June 4 and June 14, 2021. CFO Kyle Guse highlighted this milestone as an opportunity to enhance investor awareness and liquidity. Membership in these indexes is determined by market-capitalization rankings and provides automatic inclusion in growth and value style indexes, impacting approximately $10.6 trillion in assets benchmarked against Russell's U.S. Indexes.
Atossa Therapeutics, Inc. (Nasdaq: ATOS) has received approval from the Swedish Medical Product Agency to launch a Phase 2 clinical trial of its oral Endoxifen aimed at reducing mammographic breast density (MBD), a significant public health concern affecting millions of women. The study will involve about 240 pre-menopausal women and aims to assess the dose-response relationship of Endoxifen over six months. The company plans to initiate the trial once COVID-19 restrictions in Stockholm are lifted, with potential for broader future studies to evaluate Endoxifen's impact on breast cancer incidence.
Atossa Therapeutics (Nasdaq:ATOS) reported final results from its Phase 2 study of oral Endoxifen for breast cancer. The primary endpoint was met, showing a 65.1% reduction in tumor cell activity, measured by Ki-67, dropping from 25.6% to 6%. All patients achieved a Ki-67 level below 25%, which correlates with improved long-term survival. Secondary endpoints confirmed Endoxifen's safety and tolerability, with no severe adverse events. Atossa plans to advance Endoxifen toward FDA approval, targeting the unmet need for effective treatments for ER+ breast cancer.
Atossa Therapeutics, Inc. (Nasdaq: ATOS) will hold a webinar on June 9, 2021, at 8 am PT to discuss final data from its Phase 2 study of Endoxifen for breast cancer patients before surgery. The event will feature key executives, including Dr. Steven Quay, and will allow participants to engage with the management team. The company focuses on developing innovative therapies for oncology and infectious diseases, particularly breast cancer and COVID-19. Interested attendees can register via Tribe Public's platform.
Atossa Therapeutics, led by Dr. Steven Quay, published research challenging the claim that the Wuhan Institute of Virology had no COVID-19 cases. The study highlights a statistical improbability given the 4.4% prevalence of COVID-19 in Wuhan during early 2020. The researchers argue that proper testing would likely have revealed positive cases among the 590 staff members at WIV. This analysis raises serious questions about the integrity of WIV's reported COVID cases.
Physician-Scientist Dr. Steven C. Quay, CEO of Atossa Therapeutics (NASDAQ: ATOS), has been invited to brief U.S. Congress on his research concerning the origins of COVID-19. The virtual meeting will occur on May 24, 2021, where Dr. Quay will discuss evidence supporting the theory of a laboratory-origin virus from Wuhan, China. He contends existing data indicates a lab-leak scenario rather than natural zoonosis. The briefing aims to inform congressional members about these findings, which could influence future safety measures against pandemics.
Atossa Therapeutics (Nasdaq: ATOS) reported its Q1 2021 financial results, revealing no sustainable revenue and cash reserves of approximately $137.7 million. The company concluded a Phase 2 study for oral Endoxifen, which showed positive results, and received FDA clearance for expanded access treatment in an ovarian cancer patient. Operating expenses increased by 20% to $3.5 million, driven by a 47% rise in R&D costs. The company plans to expand clinical studies and explore new opportunities moving forward.
Atossa Therapeutics, Inc. (Nasdaq: ATOS) announced its participation in the Investor Summit Conference on May 18, 2021. CEO Dr. Steven Quay and CFO Kyle Guse will present at 8:45 am ET. The company focuses on developing innovative medicines for unmet medical needs, particularly in oncology and infectious diseases, including breast cancer and COVID-19. Investors can request one-on-one meetings with management after the presentation. For more details, visit Atossa's website.
Atossa Therapeutics (Nasdaq: ATOS) urges stockholders to participate in voting for proposals in its proxy statement ahead of the annual stockholder meeting on May 14, 2021. As of March 24, 2021, approximately 17.3 million shares are under lock-up and voting agreements. The company focuses on developing innovative treatments for unmet medical needs in oncology and infectious diseases, particularly breast cancer and COVID-19. For more information on voting and proposals, stockholders can refer to the proxy statement linked in the announcement.